{"entity":{"type":"insider","cik":"0001578965","url":"/insider/0001578965","json_url":"/insider/0001578965.json","name":"Koppel Adam","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":28,"n_filings":24,"first":"2013-06-28","last":"2026-04-20","span_basis":"filed_date"},"name_variants":[{"name":"Koppel Adam","source":"filing","n_filings":24,"first_seen":"2013-06-28","last_seen":"2026-04-20"}],"transactions":[{"id":6037098,"accession":"0001193125-26-164407","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193125-26-164407","line_url":"/filing/0001193125-26-164407#line-3","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"Kailera Therapeutics, Inc.","issuer_ticker":"KLRA","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":"0001578965","owner_name":"Koppel Adam","owner_display_name":"Koppel Adam","owner_url":"/insider/0001578965","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1562500.0,"shares_display":"1,562,500","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":25000000.0,"total_display":"25,000,000.00","total_whole":"25,000,000","shares_owned_after":22583268.0,"shares_owned_after_display":"22,583,268","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-04-20","filed_date":"2026-04-20","scope":"insider"},{"id":7962212,"accession":"0000899243-23-019971","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-019971","line_url":"/filing/0000899243-23-019971#line-1","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"Cerevel Therapeutics Holdings, Inc.","issuer_ticker":"CERE","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":"0001578965","owner_name":"Koppel Adam","owner_display_name":"Koppel Adam","owner_url":"/insider/0001578965","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5480052.0,"shares_display":"5,480,052","price_per_share":22.81,"price_display":"22.81","price_state":"stated","total_value":124999986.12,"total_display":"124,999,986.12","total_whole":"124,999,986","shares_owned_after":65679781.0,"shares_owned_after_display":"65,679,781","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-10-16","filed_date":"2023-10-18","scope":"insider"},{"id":4929726,"accession":"0000899243-21-032893","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-032893","line_url":"/filing/0000899243-21-032893#line-1","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"SpringWorks Therapeutics, Inc.","issuer_ticker":"SWTX","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":null,"owner_name":"Koppel Adam; Schwartz Jeffrey Lawrence; Bain Capital Life Sciences Investors, LLC; BC SW, LP","owner_display_name":"Koppel Adam","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000000.0,"shares_display":"1,000,000","price_per_share":70.25,"price_display":"70.25","price_state":"stated","total_value":70250000.0,"total_display":"70,250,000.00","total_whole":"70,250,000","shares_owned_after":4831307.0,"shares_owned_after_display":"4,831,307","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-10","filed_date":"2021-08-12","scope":"insider"},{"id":4305949,"accession":"0000899243-21-029222","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-21-029222","line_url":"/filing/0000899243-21-029222#line-3","is_derivative":false,"issuer_cik":"0001380106","issuer_name":"RAPID MICRO BIOSYSTEMS, INC.","issuer_ticker":"RPID","issuer_name_source":null,"issuer_url":"/issuer/0001380106","owner_cik":null,"owner_name":"Koppel Adam; Bain Capital Life Sciences Fund, L.P.; Schwartz Jeffrey Lawrence; BCIP Life Sciences Associates, LP; Bain Capital Life Sciences Partners, LP; Bain Capital Life Sciences Investors, LLC","owner_display_name":"Koppel Adam","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":2000000.0,"total_display":"2,000,000.00","total_whole":"2,000,000","shares_owned_after":8434560.0,"shares_owned_after_display":"8,434,560","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-19","filed_date":"2021-07-21","scope":"insider"},{"id":4707870,"accession":"0000899243-21-011153","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-011153","line_url":"/filing/0000899243-21-011153#line-1","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"SpringWorks Therapeutics, Inc.","issuer_ticker":"SWTX","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":null,"owner_name":"Koppel Adam; Bain Capital Life Sciences Investors, LLC; Schwartz Jeffrey Lawrence; BC SW, LP","owner_display_name":"Koppel Adam","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1450000.0,"shares_display":"1,450,000","price_per_share":71.5,"price_display":"71.50","price_state":"stated","total_value":103675000.0,"total_display":"103,675,000.00","total_whole":"103,675,000","shares_owned_after":5831307.0,"shares_owned_after_display":"5,831,307","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-03-09","filed_date":"2021-03-11","scope":"insider"},{"id":3167900,"accession":"0000899243-20-033765","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-033765","line_url":"/filing/0000899243-20-033765#line-1","is_derivative":false,"issuer_cik":"0001399529","issuer_name":"Dicerna Pharmaceuticals Inc","issuer_ticker":"DRNA","issuer_name_source":null,"issuer_url":"/issuer/0001399529","owner_cik":"0001578965","owner_name":"Koppel Adam","owner_display_name":"Koppel Adam","owner_url":"/insider/0001578965","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000000.0,"shares_display":"1,000,000","price_per_share":23.4,"price_display":"23.40","price_state":"stated","total_value":23400000.0,"total_display":"23,400,000.00","total_whole":"23,400,000","shares_owned_after":3080237.0,"shares_owned_after_display":"3,080,237","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-10","filed_date":"2020-12-14","scope":"insider"},{"id":3319951,"accession":"0000899243-20-030860","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-030860","line_url":"/filing/0000899243-20-030860#line-1","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"Cerevel Therapeutics Holdings, Inc.","issuer_ticker":"CERE","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":"0001578965","owner_name":"Koppel Adam","owner_display_name":"Koppel Adam","owner_url":"/insider/0001578965","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":332293.0,"shares_display":"332,293","price_per_share":10.3,"price_display":"10.30","price_state":"stated","total_value":3422617.9,"total_display":"3,422,617.90","total_whole":"3,422,618","shares_owned_after":60632356.0,"shares_owned_after_display":"60,632,356","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-11-09","filed_date":"2020-11-12","scope":"insider"},{"id":2791013,"accession":"0000899243-20-029742","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-029742","line_url":"/filing/0000899243-20-029742#line-2","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"Cerevel Therapeutics Holdings, Inc.","issuer_ticker":"CERE","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":"0001578965","owner_name":"Koppel Adam","owner_display_name":"Koppel Adam","owner_url":"/insider/0001578965","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000000.0,"shares_display":"10,000,000","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":100000000.0,"total_display":"100,000,000.00","total_whole":"100,000,000","shares_owned_after":60300063.0,"shares_owned_after_display":"60,300,063","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-27","filed_date":"2020-10-29","scope":"insider"},{"id":2419250,"accession":"0000899243-20-029321","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-029321","line_url":"/filing/0000899243-20-029321#line-1","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"Aptinyx Inc.","issuer_ticker":"APTX","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":null,"owner_name":"Koppel Adam; BCIP Life Sciences Associates, LP; Bain Capital Life Sciences Partners, LP; Schwartz Jeffrey Lawrence; Bain Capital Life Sciences Fund, L.P.; Bain Capital Life Sciences Investors, LLC","owner_display_name":"Koppel Adam","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3333333.0,"shares_display":"3,333,333","price_per_share":3.0,"price_display":"3.00","price_state":"stated","total_value":9999999.0,"total_display":"9,999,999.00","total_whole":"9,999,999","shares_owned_after":8891758.0,"shares_owned_after_display":"8,891,758","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-26","filed_date":"2020-10-27","scope":"insider"},{"id":3279923,"accession":"0000899243-20-020554","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-020554","line_url":"/filing/0000899243-20-020554#line-3","is_derivative":false,"issuer_cik":"0001528115","issuer_name":"Annexon, Inc.","issuer_ticker":"ANNX","issuer_name_source":null,"issuer_url":"/issuer/0001528115","owner_cik":null,"owner_name":"Schwartz Jeffrey Lawrence; Koppel Adam; Bain Capital Life Sciences Partners, LP; Bain Capital Life Sciences Investors, LLC; BCIP Life Sciences Associates, LP; Bain Capital Life Sciences Fund, L.P.","owner_display_name":"Schwartz Jeffrey Lawrence","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400000.0,"shares_display":"400,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":6800000.0,"total_display":"6,800,000.00","total_whole":"6,800,000","shares_owned_after":3241628.0,"shares_owned_after_display":"3,241,628","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-07-28","filed_date":"2020-07-28","scope":"insider"},{"id":2592132,"accession":"0000899243-20-003487","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-003487","line_url":"/filing/0000899243-20-003487#line-3","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":null,"owner_name":"BCIP Life Sciences Associates, LP; Koppel Adam; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Partners, LP; Schwartz Jeffrey Lawrence; Bain Capital Life Sciences Fund, L.P.","owner_display_name":"BCIP Life Sciences Associates, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":294117.0,"shares_display":"294,117","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":4999989.0,"total_display":"4,999,989.00","total_whole":"4,999,989","shares_owned_after":3979292.0,"shares_owned_after_display":"3,979,292","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-04","filed_date":"2020-02-06","scope":"insider"},{"id":2132244,"accession":"0000899243-20-001322","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-001322","line_url":"/filing/0000899243-20-001322#line-1","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"Aptinyx Inc.","issuer_ticker":"APTX","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":"0001578965","owner_name":"Koppel Adam","owner_display_name":"Koppel Adam","owner_url":"/insider/0001578965","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3333333.0,"shares_display":"3,333,333","price_per_share":3.0,"price_display":"3.00","price_state":"stated","total_value":9999999.0,"total_display":"9,999,999.00","total_whole":"9,999,999","shares_owned_after":5558425.0,"shares_owned_after_display":"5,558,425","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-01-14","filed_date":"2020-01-16","scope":"insider"},{"id":8634555,"accession":"0000899243-19-028697","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-028697","line_url":"/filing/0000899243-19-028697#line-1","is_derivative":false,"issuer_cik":"0001399529","issuer_name":"Dicerna Pharmaceuticals Inc","issuer_ticker":"DRNA","issuer_name_source":null,"issuer_url":"/issuer/0001399529","owner_cik":"0001578965","owner_name":"Koppel Adam","owner_display_name":"Koppel Adam","owner_url":"/insider/0001578965","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500000.0,"shares_display":"1,500,000","price_per_share":24.68,"price_display":"24.68","price_state":"stated","total_value":37020000.0,"total_display":"37,020,000.00","total_whole":"37,020,000","shares_owned_after":4080237.0,"shares_owned_after_display":"4,080,237","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-12-04","filed_date":"2019-12-06","scope":"insider"},{"id":7775873,"accession":"0000899243-19-027786","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-027786","line_url":"/filing/0000899243-19-027786#line-1","is_derivative":false,"issuer_cik":"0001399529","issuer_name":"Dicerna Pharmaceuticals Inc","issuer_ticker":"DRNA","issuer_name_source":null,"issuer_url":"/issuer/0001399529","owner_cik":null,"owner_name":"Bain Capital Life Sciences Fund, L.P.; Schwartz Jeffrey Lawrence; Bain Capital Life Sciences Partners, LP; Koppel Adam; BCIP Life Sciences Associates, LP; Bain Capital Life Sciences Investors, LLC","owner_display_name":"Bain Capital Life Sciences Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1750000.0,"shares_display":"1,750,000","price_per_share":22.03,"price_display":"22.03","price_state":"stated","total_value":38552500.0,"total_display":"38,552,500.00","total_whole":"38,552,500","shares_owned_after":5580237.0,"shares_owned_after_display":"5,580,237","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-11-19","filed_date":"2019-11-21","scope":"insider"},{"id":7858007,"accession":"0000899243-19-023936","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-19-023936","line_url":"/filing/0000899243-19-023936#line-3","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"SpringWorks Therapeutics, Inc.","issuer_ticker":"SWTX","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":null,"owner_name":"Schwartz Jeffrey Lawrence; Koppel Adam; Bain Capital Life Sciences Investors, LLC; BC SW, LP","owner_display_name":"Schwartz Jeffrey Lawrence","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":2700000.0,"total_display":"2,700,000.00","total_whole":"2,700,000","shares_owned_after":7281307.0,"shares_owned_after_display":"7,281,307","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-09-17","filed_date":"2019-09-19","scope":"insider"},{"id":7830833,"accession":"0000899243-19-015281","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-015281","line_url":"/filing/0000899243-19-015281#line-1","is_derivative":false,"issuer_cik":"0001399529","issuer_name":"Dicerna Pharmaceuticals Inc","issuer_ticker":"DRNA","issuer_name_source":null,"issuer_url":"/issuer/0001399529","owner_cik":null,"owner_name":"Bain Capital Life Sciences Fund, L.P.; BCIP Life Sciences Associates, LP; Bain Capital Life Sciences Partners, LP; Bain Capital Life Sciences Investors, LLC; Schwartz Jeffrey Lawrence; Koppel Adam","owner_display_name":"Bain Capital Life Sciences Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1600000.0,"shares_display":"1,600,000","price_per_share":12.5,"price_display":"12.50","price_state":"stated","total_value":20000000.0,"total_display":"20,000,000.00","total_whole":"20,000,000","shares_owned_after":7330237.0,"shares_owned_after_display":"7,330,237","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-29","filed_date":"2019-05-31","scope":"insider"},{"id":6717398,"accession":"0000899243-18-020659","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-020659","line_url":"/filing/0000899243-18-020659#line-2","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"Replimune Group, Inc.","issuer_ticker":"REPL","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":null,"owner_name":"Schwartz Jeffrey Lawrence; Bain Capital Life Sciences Fund, L.P.; BCIP Life Sciences Associates, LP; Bain Capital Life Sciences Partners, LP; Bain Capital Life Sciences Investors, LLC; Koppel Adam","owner_display_name":"Schwartz Jeffrey Lawrence","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500000.0,"shares_display":"500,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":7500000.0,"total_display":"7,500,000.00","total_whole":"7,500,000","shares_owned_after":2838968.0,"shares_owned_after_display":"2,838,968","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-07-24","filed_date":"2018-07-26","scope":"insider"},{"id":6467183,"accession":"0000899243-18-018155","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-018155","line_url":"/filing/0000899243-18-018155#line-2","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"Aptinyx Inc.","issuer_ticker":"APTX","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":"0001578965","owner_name":"Koppel Adam","owner_display_name":"Koppel Adam","owner_url":"/insider/0001578965","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400000.0,"shares_display":"400,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":6400000.0,"total_display":"6,400,000.00","total_whole":"6,400,000","shares_owned_after":2225092.0,"shares_owned_after_display":"2,225,092","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-25","filed_date":"2018-06-26","scope":"insider"},{"id":6677531,"accession":"0000899243-18-002535","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-002535","line_url":"/filing/0000899243-18-002535#line-2","is_derivative":false,"issuer_cik":"0001578965","issuer_name":"Solid Biosciences Inc.","issuer_ticker":"SLDB","issuer_name_source":null,"issuer_url":"/issuer/0001578965","owner_cik":"0001578965","owner_name":"Koppel Adam","owner_display_name":"Koppel Adam","owner_url":"/insider/0001578965","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300000.0,"shares_display":"300,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":4800000.0,"total_display":"4,800,000.00","total_whole":"4,800,000","shares_owned_after":1989444.0,"shares_owned_after_display":"1,989,444","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-01-30","filed_date":"2018-02-01","scope":"insider"},{"id":4217697,"accession":"0000899243-17-029256","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-17-029256","line_url":"/filing/0000899243-17-029256","is_derivative":false,"issuer_cik":"0001267813","issuer_name":"MARINUS PHARMACEUTICALS INC","issuer_ticker":"MRNS","issuer_name_source":null,"issuer_url":"/issuer/0001267813","owner_cik":null,"owner_name":"Bain Capital Life Sciences Fund, L.P.; Bain Capital Life Sciences Partners, LP; BCIP Life Sciences Associates, LP; Koppel Adam; Bain Capital Life Sciences Investors, LLC; Schwartz Jeffrey Lawrence","owner_display_name":"Bain Capital Life Sciences Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":150000.0,"shares_display":"150,000","price_per_share":7.431133156,"price_display":"7.43","price_state":"stated","total_value":1114669.9734,"total_display":"1,114,669.97","total_whole":"1,114,670","shares_owned_after":4032682.0,"shares_owned_after_display":"4,032,682","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-12-19","filed_date":"2017-12-19","scope":"insider","n_lines":2},{"id":4352432,"accession":"0000899243-17-029183","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-17-029183","line_url":"/filing/0000899243-17-029183#line-3","is_derivative":false,"issuer_cik":"0001399529","issuer_name":"Dicerna Pharmaceuticals Inc","issuer_ticker":"DRNA","issuer_name_source":null,"issuer_url":"/issuer/0001399529","owner_cik":null,"owner_name":"Koppel Adam; Bain Capital Life Sciences Partners, LP; BCIP Life Sciences Associates, LP; Schwartz Jeffrey Lawrence; Bain Capital Life Sciences Fund, L.P.; Bain Capital Life Sciences Investors, LLC","owner_display_name":"Koppel Adam","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":285000.0,"shares_display":"285,000","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":1995000.0,"total_display":"1,995,000.00","total_whole":"1,995,000","shares_owned_after":285000.0,"shares_owned_after_display":"285,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-12-18","filed_date":"2017-12-19","scope":"insider"},{"id":4217689,"accession":"0000899243-17-029256","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-17-029256","line_url":"/filing/0000899243-17-029256#line-3","is_derivative":false,"issuer_cik":"0001267813","issuer_name":"MARINUS PHARMACEUTICALS INC","issuer_ticker":"MRNS","issuer_name_source":null,"issuer_url":"/issuer/0001267813","owner_cik":null,"owner_name":"Bain Capital Life Sciences Fund, L.P.; Bain Capital Life Sciences Partners, LP; BCIP Life Sciences Associates, LP; Koppel Adam; Bain Capital Life Sciences Investors, LLC; Schwartz Jeffrey Lawrence","owner_display_name":"Bain Capital Life Sciences Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300000.0,"shares_display":"300,000","price_per_share":7.5048,"price_display":"7.50","price_state":"stated","total_value":2251440.0,"total_display":"2,251,440.00","total_whole":"2,251,440","shares_owned_after":4127453.0,"shares_owned_after_display":"4,127,453","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-12-18","filed_date":"2017-12-19","scope":"insider"},{"id":4217685,"accession":"0000899243-17-029256","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-17-029256","line_url":"/filing/0000899243-17-029256","is_derivative":false,"issuer_cik":"0001267813","issuer_name":"MARINUS PHARMACEUTICALS INC","issuer_ticker":"MRNS","issuer_name_source":null,"issuer_url":"/issuer/0001267813","owner_cik":null,"owner_name":"Bain Capital Life Sciences Fund, L.P.; Bain Capital Life Sciences Partners, LP; BCIP Life Sciences Associates, LP; Koppel Adam; Bain Capital Life Sciences Investors, LLC; Schwartz Jeffrey Lawrence","owner_display_name":"Bain Capital Life Sciences Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":822547.0,"shares_display":"822,547","price_per_share":8.095210310778594,"price_display":"8.10","price_state":"stated","total_value":6658690.9555,"total_display":"6,658,690.96","total_whole":"6,658,691","shares_owned_after":4530335.0,"shares_owned_after_display":"4,530,335","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-12-15","filed_date":"2017-12-19","scope":"insider","n_lines":2},{"id":3039537,"accession":"0001127602-16-054895","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-16-054895","line_url":"/filing/0001127602-16-054895#line-1","is_derivative":false,"issuer_cik":"0000875045","issuer_name":"BIOGEN INC.","issuer_ticker":"BIIB","issuer_name_source":null,"issuer_url":"/issuer/0000875045","owner_cik":"0001578965","owner_name":"Koppel Adam","owner_display_name":"Koppel Adam","owner_url":"/insider/0001578965","role":"Officer (EVP, Strategy and Bus. Dev)","role_mark":"O","role_mark_label":"Officer (EVP, Strategy and Bus. Dev)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Strategy and Bus. Dev.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":555.0,"shares_display":"555","price_per_share":290.0,"price_display":"290.00","price_state":"stated","total_value":160950.0,"total_display":"160,950.00","total_whole":"160,950","shares_owned_after":2402.1123,"shares_owned_after_display":"2,402.11","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-06-06","filed_date":"2016-06-07","scope":"insider"},{"id":2789706,"accession":"0001127602-16-049044","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-16-049044","line_url":"/filing/0001127602-16-049044#line-1","is_derivative":false,"issuer_cik":"0000875045","issuer_name":"BIOGEN INC.","issuer_ticker":"BIIB","issuer_name_source":null,"issuer_url":"/issuer/0000875045","owner_cik":"0001578965","owner_name":"Koppel Adam","owner_display_name":"Koppel Adam","owner_url":"/insider/0001578965","role":"Officer (EVP, Strategy and Bus. Dev)","role_mark":"O","role_mark_label":"Officer (EVP, Strategy and Bus. Dev)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Strategy and Bus. Dev.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":102.0,"shares_display":"102","price_per_share":275.0,"price_display":"275.00","price_state":"stated","total_value":28050.0,"total_display":"28,050.00","total_whole":"28,050","shares_owned_after":1848.1123,"shares_owned_after_display":"1,848.11","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-04-06","filed_date":"2016-04-07","scope":"insider"},{"id":5066975,"accession":"0001181431-13-037300","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-13-037300","line_url":"/filing/0001181431-13-037300#line-2","is_derivative":false,"issuer_cik":"0001070081","issuer_name":"PTC THERAPEUTICS, INC.","issuer_ticker":"PTCT","issuer_name_source":null,"issuer_url":"/issuer/0001070081","owner_cik":"0001578965","owner_name":"Koppel Adam","owner_display_name":"Koppel Adam","owner_url":"/insider/0001578965","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1250000.0,"shares_display":"1,250,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":18750000.0,"total_display":"18,750,000.00","total_whole":"18,750,000","shares_owned_after":2333333.0,"shares_owned_after_display":"2,333,333","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-06-25","filed_date":"2013-06-28","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":12,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":8,"open_market":true},{"code":"S","label":"Open-market sale","n":4,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":12},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0002096997","name":"Kailera Therapeutics, Inc.","url":"/issuer/0002096997","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2026-04-20","last_seen":"2026-04-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001805387","name":"Cerevel Therapeutics Holdings, Inc.","url":"/issuer/0001805387","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2020-10-29","last_seen":"2023-10-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001773427","name":"SpringWorks Therapeutics, Inc.","url":"/issuer/0001773427","role":"Ten percent owner","n_filings":3,"first_seen":"2019-09-19","last_seen":"2021-08-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001380106","name":"RAPID MICRO BIOSYSTEMS, INC.","url":"/issuer/0001380106","role":"Ten percent owner","n_filings":1,"first_seen":"2021-07-21","last_seen":"2021-07-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001399529","name":"Dicerna Pharmaceuticals Inc","url":"/issuer/0001399529","role":"Director, Ten percent owner","n_filings":5,"first_seen":"2017-12-19","last_seen":"2020-12-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001674365","name":"Aptinyx Inc.","url":"/issuer/0001674365","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2018-06-26","last_seen":"2020-10-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001528115","name":"Annexon, Inc.","url":"/issuer/0001528115","role":"Ten percent owner","n_filings":1,"first_seen":"2020-07-28","last_seen":"2020-07-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001787306","name":"Arcutis Biotherapeutics, Inc.","url":"/issuer/0001787306","role":"Ten percent owner","n_filings":1,"first_seen":"2020-02-06","last_seen":"2020-02-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001737953","name":"Replimune Group, Inc.","url":"/issuer/0001737953","role":"Director","n_filings":1,"first_seen":"2018-07-26","last_seen":"2018-07-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001707502","name":"Solid Biosciences Inc.","url":"/issuer/0001707502","role":"Director","n_filings":1,"first_seen":"2018-02-01","last_seen":"2018-02-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001267813","name":"MARINUS PHARMACEUTICALS INC","url":"/issuer/0001267813","role":"Ten percent owner","n_filings":1,"first_seen":"2017-12-19","last_seen":"2017-12-19"},{"type":"issuer","type_label":"ISSUER","cik":"0000875045","name":"BIOGEN INC.","url":"/issuer/0000875045","role":"Officer (EVP, Strategy and Bus. Dev)","n_filings":2,"first_seen":"2016-04-07","last_seen":"2016-06-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001070081","name":"PTC THERAPEUTICS, INC.","url":"/issuer/0001070081","role":"Director","n_filings":1,"first_seen":"2013-06-28","last_seen":"2013-06-28"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001578965","retrieved_at":"2026-08-22T11:03:19+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}